A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 701–800 of 1,138
Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist
Malik, A., Kardashian, A. A., Zakharia, K., Bowlus, C. L., & Tabibian, J. H. (2019) · Liver Research · doi:10.1016/j.livres.2019.04.001 · Cited by 8
Self-citationNonalcoholic Fatty Liver Disease
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_9 · Cited by 6
de Abreu, E. S., Fernandes, G. P., Lacerda, H., Reginato, P. H., Neves, H. A. F., Gonzalez, C. D. S., Eaton, J. E., & Cançado, G. G. L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70094 · Cited by 9
“Dose-dependent pruritus was the most common side effect noted in the POISE trial [5, 6].”
InfluentialGazda, J., Dražilová, S., Janíčko, M., Grgurević, I., Kanižaj, T. F., Koller, T., Bodorovska, B., Božin, T., Mijić, M., Rob, Z., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060495 · Cited by 9
“Obeticholic acid (OCA) or fibrates can be offered to non-responders, however, fibrates are currently off-label [7,8].”
BackgroundWang, Y., Li, Y., Wang, X., Gaćeša, R., Zhang, J., Zhou, L., & Wang, B. (2020) · Disease Markers · doi:10.1155/2020/8460883 · Cited by 7
Liu, Y., Tian, S., Jia, G., Han, Z., Guo, C., Shang, Y., & Han, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00119 · Cited by 14
Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis
Corpechot, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.010 · Cited by 6
Bile Acids as Signaling Molecules
Claudel, T., & Trauner, M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch25 · Cited by 9
Self-citationAdvances in the treatment of severe alcoholic hepatitis
Wang, W., Xu, Y., Chang, J., & Gao, Y. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1479247 · Cited by 6
“in, Neomyci n, Metronid azole and Vancomy cin [62] — reduce the”
BackgroundKim, E. Y., & Lee, J. M. (2022) · Antioxidants · doi:10.3390/antiox11020370 · Cited by 8
“FXR activation using obeticholic acid (OCA) has been already approved for the treatment of primary biliary cholangitis and is currently underway for the treatment of nonalcoholic steatohepatitis [38,39].”
BackgroundInvestigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis
Akepati, P. R., & Gochanour, E. M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2348743 · Cited by 8
Gazda, J., Janicko, M., Drazilova, S., Grgurevic, I., Kanizaj, T. F., Koller, T., Bodorovska, B., Mijic, M., Mikolasevic, I., Stromar, I. K., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/9928065 · Cited by 6
Cho, S. I., Lee, J., Lim, J. H., Park, J., Kim, M., Kim, T. Y., Kim, T. Y., Lee, K., Keam, B., Han, S. S., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3129 · Cited by 7
Fibrates and Fibrate-induced Liver Injury in Primary Biliary Cholangitis
Vanasco, A., & vanSonnenberg, E. (2023) · Gene Expression · doi:10.14218/ge.2023.00015 · Cited by 5
Martins, A., Khakoo, N. S., Reddy, A., Reynolds, J. M., Corpechot, C., Rousseau, A., Murad, M., Sultan, S., & Levy, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001465 · Cited by 12
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6
“From a comparative perspective, OCA and fibrates both achieve ALP reduction, but fibrates often provide greater biochemical response and potential pruritus relief, whereas OCA is limited by dose-dependent pruritus and contraindications in cirrhosis [15,22,27].”
InfluentialOlveira, A., Carmona, J. Y., Amaral, C., Tejedor, M., Eirás, P., Hernández-Pérez, M., Cabredo, C. G. S., Spigarelli, I. M., Ferrer, C. S., Morales-Arráez, D. E., et al. (2021) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2021.8174/2021 · Cited by 5
Brunet, E., Hernández, L., Miquel, M., Sánchez‐Delgado, J., Dalmau, B., Valero, O., Vergara, M., & Casas, M. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.08.002 · Cited by 6
Levy, C., Jones, D. E. J., Mayo, M. J., Bowlus, C. L., Kowdley, K. V., Hirschfield, G. M., Liu, J., Burk, C., Carroll, S., Crittenden, D. B., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70630 · Cited by 7
“First-line UDCA does not relieve PBC-related pruritus [25], and second-line obeticholic acid has been known to cause pruritus [26].”
Self-citationChallenges in the diagnosis and management of AIH-PBC syndrome
Gerussi, A., Invernizzi, P., & Carbone, M. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101224 · Cited by 5
Self-citationRogalska, M., Błachnio-Zabielska, A. U., Zabielski, P., Janica, J. R., Roszczyc-Owsiejczuk, K., Pogodzińska, K., Andrzejuk, A., Dâbrowski, A., Flisiak, R., & Rogalski, P. (2025) · Nutrients · doi:10.3390/nu17071097 · Cited by 9
“Obeticholic acid (OCA), a second-line drug for PBC, has an unfavorable impact on the lipid profile in patients with PBC, as it has been associated with a reduction in HDL and an increase in LDL [26].”
Primary biliary cholangitis: Treatment options finally expand
Levy, C. (2017) · Hepatology · doi:10.1002/hep.29053 · Cited by 5
“This approval was largely based on results of the PBC OCA International Study of Efficacy (POISE) trial, recently published by Nevens and colleagues.((6)) In this study, patients with PBC with persistently elevated ALP above 1.”
MethodSahu, R., Mishra, R., & Majee, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797485 · Cited by 5
“Several associated side effects are increases of HDL and reduction of LDL cholesterol, although earlier studies were different, ~59% reported pruritus which is encountered almost at every dose (dosedependent) [57,91,95].”
BackgroundResultHyocholic acid: A novel therapeutic strategy for metabolic syndrome
Rong, B., Zhang, Q., Zhang, X., Zhang, N., Shen, Z., Pang, Y., Lin, X. K., Liu, D., & Yang, X. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100093 · Cited by 5
Primary biliary cholangitis: Diagnosis and treatment
Chew, M. T., & Bowlus, C. L. (2018) · Liver Research · doi:10.1016/j.livres.2018.03.004 · Cited by 6
Self-citationThomas, H. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.143 · Cited by 5
Ma, Y., Wang, H., Yang, J., Xin, M., & Wu, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175790 · Cited by 6
Kim, E. Y., & Lee, J. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125825 · Cited by 8
Kılavuz, H., Turan, Ü., YOLDAŞ, A., Tolun, F. İ., Tanrıverdi, B., Yaylalı, A., Yaman, A., Yener, K., & İrkörücü, O. (2021) · Acta Cirúrgica Brasileira · doi:10.1590/acb360902 · Cited by 5
Tanaka, A., Hirohara, J., Nakano, T., Yagi, M., Namisaki, T., Yoshiji, H., Nakanuma, Y., Takikawa, H., & Japan PBC Study Group (JPBCSG) (2018) · Hepatology Research · doi:10.1111/hepr.13068 · Cited by 5
Han, X., Lin, C., Liu, H., Li, S., Hu, B., & Zhang, L. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4562 · Cited by 5
“However, UDCA is ineffective in about 40% of PBC patients at risk of disease progression (Lindor et al., 2019), and about 50% of patients do not respond to OCA treatment (Nevens et al., 2016).”
BackgroundPalmiotti, A., de Vries, H. D., Hovingh, M. V., Koehorst, M., Mulder, N. L., Verkade, E., Veentjer, M. K., van Dijk, T. H., Bloks, V. W., Havinga, R., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092495 · Cited by 5
Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis
Fejfar, T., Vaňásek, T., & Hůlek, P. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.084 · Cited by 5
Terracciani, F., Vincentis, A. D., D’Amato, D., Cristoferi, L., Gerussi, A., Invernizzi, P., Scaravaglio, M., Vanni, E., Campion, D., Morgando, A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101448 · Cited by 13
“10,11 The trial demonstrated that OCA treatment led to sustained reduction and/or stabilisation of the main prognostic determinants in PBC, namely alkaline phosphatase (ALP) and bilirubin.”
Self-citationTreatment of PBC —A step forward
Carbone, M., & Invernizzi, P. (2017) · Liver International · doi:10.1111/liv.13353 · Cited by 5
Self-citationPrognostic Scoring Systems in Primary Biliary Cholangitis
Scaravaglio, M., & Carbone, M. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.005 · Cited by 6
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
“Clinical evaluation in primary biliary cholangitis demonstrated significant biochemical and histological improvements, underscoring the therapeutic potential of FXR activation in metabolic and inflammatory disorders [207].”
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“In studies with comparable populations, response rates for these novel PPAR agonists have exceeded those seen in the ‘POISE’ trial with OCA [24], but no head-to-head studies are available so far for any second-line treatment in PBC.”
InfluentialWagner, M., & Fickert, P. (2018) · Liver International · doi:10.1111/liv.13744 · Cited by 5
Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
Schattenberg, J. M., Bañales, J. M., Hirschfield, G. M., Trivedi, P., Cable, E. E., McWherter, C. A., Billin, A. N., Crittenden, D. B., & Budas, G. R. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70598 · Cited by 5
“Moreover, OCA has been shown to exacerbate pruritus [12], and there has been concern about the risk of hepatotoxicity in patients with more advanced disease and evidence of portal hypertension [11].”
InfluentialSelf-citationde Abreu, E. S., Reginato, P. H., Pitanga, J. F. J., Borges, P. N., Soret, P., Corpechot, C., & Cançado, G. G. L. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09044-5 · Cited by 6
“The POISE trial demonstrated a notable decrease in ALP levels and normalization of bilirubin compared to placebo, albeit accompanied by exacerbation of pruritus [8].”
InfluentialPrimary biliary cholangitis: advances in understanding and management
Smith, A., Giles, B., & Aspinall, R. (2022) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0450 · Cited by 6
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 9
“Since 2016, the FDA has approved obeticholic acid (OCA), elafibranor, and seladelpar as second-line treatments, specifically for patients who are non-responsive or intolerant to UDCA [34–36].”
Gairola, A., Wetten, A., & Dyson, J. K. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2343789 · Cited by 5
“UDCA, while improving biochemistry and long-term outcomes in PBC [7,8], does not improve pruritus [9], and OCA exacerbates itch in a proportion of patients [10].”
BackgroundRisk Stratification in Primary Biliary Cholangitis
(2023) · doi:10.20944/preprints202307.1192.v1 · Cited by 5
The case for combining treatments for primary sclerosing cholangitis
Abbing, R. L. P. R., de Lannoy, L. M., & van de Graaf, S. F. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30173-0 · Cited by 5
Bezafibrate for primary biliary cholangitis: time to act on the evidence
Corpechot, C., Londoño, M., Villamil, A., Ytting, H., Tanaka, A., & Beuers, U. H. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01135-y · Cited by 8
Self-citationThe Role of Liver Transplantation in Alcoholic Hepatitis
Ma, M., Falloon, K., Chen, P., Saberi, B., Pustavoitau, A., Ozdogan, E., Li, Z., Philosophe, B., Cameron, A. M., & Gurakar, A. O. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618780339 · Cited by 6
Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis
Chen, Y., Zheng, K., Da, G., Wang, X., Wei, Y., Wang, G., Zhang, F., & Wang, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406268 · Cited by 7
“Obeticholic acid (OCA), an FXR agonist and second-line treatment for PBC, commonly causes pruritus [4], leading 4% of the patients to discontinue it due to severity [5].”
High-fat diet exacerbates atopic dermatitis through alterations in the gut microbiome
Tabata, K., Ikarashi, N., Yoshida, R., Shinozaki, Y., Kato, Y., Kon, R., Iwasaki, Y., Yokoyama, K., Saito, R., Sakai, H., et al. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110164 · Cited by 5
Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance
Chen, Q., Xin, L. I. U., & Jiang, Z.-H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.01.001 · Cited by 6
Gerussi, A., & Carbone, M. (2020) · Wiley eBooks · doi:10.1002/9781119532637.ch7 · Cited by 5
Primary biliary cholangitis. Treatment options in 2025. A narrative review
Angelara, M., Papachristou, K., Papatheodoridi, Μ., Ansari, N. N., Karagiannakis, D. S., & Ανδρουτσάκος, Θ. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1698833 · Cited by 8
Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Cumpian, N. A., Choi, G., & Saab, S. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08742-w · Cited by 6
“Four phase three clinical trial evaluating obeticholic acid (OCA), bezafibrate, seladelpar, and elafibranor, were identified (Table 1) [17–20].”
InfluentialReviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2537192 · Cited by 4
“OCA was conditionally approved in 2016 after the results of the phase 3 POISE trial that demonstrated about 56–59% improvement after one year of treatment [33].”
Self-citationXi, L., Shi, A., Shen, T., Wang, G., Wei, Y., & Guo, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1197856 · Cited by 4
“However, the use of the FXR agonist obeticholic acid (OCA) has resulted in several side effects, including pruritus and an increased risk of hepatic decompensation in cirrhotic PBCpatients (Nevens et al., 2016).”
BackgroundYue, S. R., Tan, Y. L., Gong, L., & Liao, F. (2026) · iScience · doi:10.1016/j.isci.2026.114961 · Cited by 6
“104 However, the therapeutic effects of direct BA supplementation may be transient, limited primarily to the treatment period, with challenges in maintaining efficacy after discontinuation.”
Zaidi, M. H., Haider, Z., Sadia, F., Tayyab, M., Tariq, M., Ans, H., Javaid, M. B., Khan, A., Ahmad, M. H., Rasheed, R., et al. (2025) · JGH Open · doi:10.1002/jgh3.70196 · Cited by 4
Wetten, A., Jones, D. E. J., & Dyson, J. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1940135 · Cited by 4
Self-citationvan Hooff, M. C., de Veer, R. C., Werner, E., Beuers, U. H., Drenth, J. P. H., Cuperus, F. J. C., van Hoek, B., Veldt, B. J., Klemt‐Kropp, M., van Meer, S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003879 · Cited by 7
Self-citationWen, F., Bian, D., Wu, X., Liu, R., Wang, C., & Gan, J. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14021 · Cited by 5
“…information The First Affiliated Hospital of Soochow University; Jiangsu Provincial Health Commission Medical Research K E Y W O R D S auraptene, FXR, hepatic steatosis, inflammation, NASH of primary biliary cirrhosis and NASH (Fiorucci et al., 2019; Hindson, 2020; Nevens et al., 2016).”
BackgroundExploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 7
Limo, J. D. C., Romero-Gutiérrez, M., & Martín, J. R. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.6883/2020 · Cited by 4
Contreras-Omaña, R., Velasco, J. A. V.-R., Castro‐Narro, G., Trujillo-Benavides, O. E., Zamarripa-Dorsey, F., Dorantes, Á. A. R., Muñoz-Espinosa, L. E., Aiza-Haddad, I., Castillo-Barradas, M., Reyes, E. C., et al. (2021) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2021.04.003 · Cited by 6
Bile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 6
Zhu, F., Ding, Y., Chen, L., Fang, R., Huang, C., Liu, E., Wang, Y., Su, Y. J., & Ge, C. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01252-5 · Cited by 6
“However, its application is associated with a high incidence of adverse effects [29].”
Primary Biliary Cholangitis and Ursodeoxycholic Acid: Therapy Progress and Challenges
Vinnitskaya, E. V., Absandze, K. G., Архипова, Е. В., Ivanov, A. N., Сергеевна, С. Е., & Sandler, Y. G. (2019) · Doctor Ru · doi:10.31550/1727-2378-2019-158-3-33-39 · Cited by 4
“В качестве наиболее распространенных побочных эффектов, связанных с приемом препарата, отмечены кожный зуд, усталость, боль в животе и суставах, головокружение, запоры [14, 39].”
An update on novel investigational agents for the treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573638 · Cited by 4
Self-citationLondoño, M., & Díaz‐González, Á. (2022) · Liver International · doi:10.1111/liv.15379 · Cited by 5
“18 All these results should be interpreted with caution because the study has several limitations that hamper the applicability of the results: (1) It is a retrospective analysis with a relatively small sample size; (2) It lacks a control group of patients with PBC- related cirrhosis without OCA; (3) Histology and tra…”
ResultWang, S., Dong, V., Montaño‐Loza, A. J., & Mason, A. L. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.163 · Cited by 6
Clinical Trials in PBC Going Forward
Corpechot, C. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1687852 · Cited by 4
Bao, J., Zhang, X., Ye, M., Yang, Y., Xu, L., He, L., Guo, J., Yao, D., Wang, S., Zhang, J., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00708 · Cited by 6
Chang, Y., Xia, Y., Liu, X., Yu, P., Fan, F., Shi, Y., Yan, S., & Yan, S. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115535 · Cited by 4
The impact of undiagnosed primary biliary cholangitis
Garrido, I., Liberal, R., Cardoso, M. J., & Macedo, G. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002268 · Cited by 5
Diagnosis and Treatment of Primary Biliary Cholangitis
Kim, K. (2023) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2023.002 · Cited by 5
Harrington, L., Ovadia, C., Heneghan, M. A., & Williamson, C. (2024) · Obstetric Medicine · doi:10.1177/1753495x241293324 · Cited by 7
Losurdo, G., Gravina, A. G., Maroni, L., Gabrieletto, E. M., Ianiro, G., Ferrarese, A., Visintin, A., Frazzoni, L., Pellegatta, G., Sessa, A., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.008 · Cited by 5
Eaton, J. E., & Gores, G. J. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30084-6 · Cited by 4
Novel Bile Acid Therapies for Liver Disease.
Karpen, S. J. (2018) · Europe PMC (PubMed Central) · Cited by 4
Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Bowlus, C. L., & Levy, C. (2023) · Hepatology · doi:10.1097/hep.0000000000000556 · Cited by 4
Self-citationPaik, W. H., Park, J. K., Chung, M. J., Huh, G., Park, C. H., Lee, S. H., Jeong, H. S., Kim, H. J., & Park, D. H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0629 · Cited by 10
Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features
Mané, F., Cardoso, H., Liberal, R., Lopes, S., Pereira, P., Gonçalves, R., & Macedo, G. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.11.006 · Cited by 5
Hasan, M. N., Wang, H., Luo, W., Clayton, Y. D., Gu, L., Du, Y., Palle, S. K., Chen, J., & Li, T. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100649 · Cited by 4
Tanaka, A., Abe, M., Namisaki, T., Shimoda, S., Zeniya, M., Ido, A., Yoshiji, H., Ohira, H., Harada, K., Kakuda, Y., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100283 · Cited by 5
Novel Therapies for Managing Cholestasis
Santiago, P., & Levy, C. (2020) · Clinical Liver Disease · doi:10.1002/cld.886 · Cited by 4
Obeticholic acid for treatment of NAFLD—A drug in search of a disease
Malnick, S. D. H., Mildiner, S., & Neuman, M. G. (2020) · GastroHep · doi:10.1002/ygh2.397 · Cited by 4
Chung, Y., Tsou, H. L. P., Heneghan, M. A., Chokshi, S., & Riva, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020605 · Cited by 4
Cilofexor for the Treatment of Nonalcoholic Steatohepatitis
Pοlyzos, S. A., Xanthopoulos, K., & Kountouras, J. (2021) · Current Vascular Pharmacology · doi:10.2174/1570161119666211209161023 · Cited by 4
Bittermann, T., & Schaubel, D. E. (2024) · Hepatology · doi:10.1097/hep.0000000000001198 · Cited by 4
Obeticholsäure bei primär biliärer Cholangitis
Gerken, G., & Nitschmann, S. (2017) · Der Internist · doi:10.1007/s00108-016-0185-9 · Cited by 4
Recurrent Disease After Liver Transplantation
Lim, N., & Lake, J. R. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00507-z · Cited by 6
Serum Ghrelin Concentration in Patients With Primary Biliary Cirrhosis (PBC)
Naguib, R., Fayed, A. A., Elkemary, E., & Naguib, H. (2021) · Cureus · doi:10.7759/cureus.20288 · Cited by 5
“It is characterized by inflammation of the small and medium-sized bile ducts, destruction of interlobular bile ductules, cholestasis, cirrhosis, end-stage liver disease, and death [21-23].”
BackgroundLew, D., Sundaram, V., Barrows, B., Lo, S. K., & Gaddam, S. (2017) · ACG Case Reports Journal · doi:10.14309/crj.2017.77 · Cited by 3
“Future therapies include obeticholic acid, which was recently approved by the FDA to treat primary biliary cholangitis.(14) It is currently under study in a placebo-controlled trial for PSC (ClinicalTrials.”
BackgroundThe Depletion of Plasma Cells but Not CD20 + B Cells Alleviates Primary Biliary Cholangitis
Zhang, X., Jia, H., Ran, Y., Chu, H., Shen, M., Yang, H., Han, Z., Wang, X., Li, J., Li, Y., et al. (2025) · Liver International · doi:10.1111/liv.70373 · Cited by 3
“Current second-line treatments such as obeticholic acid and fibrates can improve biochemical parameters in PBC patients but still provide limited prognostic benefits and may cause side effects such as pruritus or elevated transaminases and creatinine levels [3–5].”
Gerussi, A., Nofit, E., Bernasconi, D. P., Kroll, C., Groß, F., Schregel, I., Marini, A., Cristoferi, L., Malinverno, F., Papp, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70134 · Cited by 4
“The latest include the use of second‐line therapies such as obeticholic acid (OCA) [8] and peroxisome proliferator‐activated receptor (PPAR) agonists for patients who do not respond adequately to UDCA [9–11].”
Self-citationChronic Liver Disease – What’s New?
Effandie, E., & Gupte, G. L. (2023) · The Indian Journal of Pediatrics · doi:10.1007/s12098-023-04819-y · Cited by 6
Mandea, M., Iacob, S. M., Ghioca, M. C., Gheorghe, C., & Gheorghe, L. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228240 · Cited by 5
“Subsequently, in 2024, the license was withdrawn by the EMA and questioned by the FDA; as a result, all patients in Romania discontinued the treatment [13,16,17].”
InfluentialEarly assessment of treatment response in primary biliary cholangitis: key to timely management
Koky, T., Dražilová, S., Janíčko, M., Toporcerová, D., Gazda, J., & Jarčuška, P. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04138-w · Cited by 7
“Patients treated with OCA were significantly more likely to have a biochemical response in the POISE registration study compared to placebo [17].”
Gerussi, A., Sebode, M., Nofit, E., Stoelinga, A., Bernasconi, D. P., Leburgue, A., Invernizzi, P., Schramm, C., van Hoek, B., TINIAKOS, D. G., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001793 · Cited by 3
Self-citation
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.